This research has found that MMP9 is the primary core target for the treatment of AD with artesunate and artemether, while HSP90AA1, EGFR, PTGS2, and CASP3 are the most significant targets for the treatment of AD with artemisinin, dihydroartemisinin, artemether, and arteether, respectively. Here, PTGS2 is linked to Alzheimer disease.